16/04/2026 – AB Science provides an update on its clinical development program Download PDF Category: 202616 April 2026Post navigationPreviousPrevious post:AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALSNextNext post:New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patientsRelated PostsAB Science web conference of October 14, 202614 October 2026Web conference on October 14, 2026, from 6:00 p.m. to 7:30 p.m.12 October 2026Revenues for the first half of 2026 and update on AB Science’s activities9 October 2026AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
